A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Platform Study Evaluating the Efficacy and Safety of Interventions in Participants With Moderately to Severely Active Crohn's Disease
Latest Information Update: 06 Feb 2025
At a glance
- Drugs PTG 200 (Primary)
- Indications Crohn's disease
- Focus Proof of concept; Therapeutic Use
- Acronyms PRISM; PRISM-SCARLET
- Sponsors Janssen Research & Development; Janssen-Cilag
- 07 Jan 2022 Status changed from active, no longer recruiting to discontinued. Reason the study was stopped: IAC completed review of futility analysis data & determined that futility criteria were met. As a result, Janssen made decision to stop trial immediately.
- 01 Dec 2021 Status changed from recruiting to active, no longer recruiting.
- 11 Nov 2021 This trial has been discontinued in Germany, according to European Clinical Trials Database record.